Dendrimer nanohybrid carrier systems: an expanding horizon for targeted drug and gene delivery

Kesharwani P 1 , Gothwal A 2 , Iyer AK 3 , Jain K 4 , Chourasia MK 5 , Gupta U 6

Affiliations 

  • 1 Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Malaysia; Pharmaceutics Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh 226031, India. Electronic address: prashantdops@gmail.com
  • 2 Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305801, India
  • 3 Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, School of Medicine, Detroit, MI 48201, USA
  • 4 National Institute of Pharmaceutical Education and Research (NIPER Raebareli), Raebareli, Uttar Pradesh 229010, India
  • 5 Pharmaceutics Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh 226031, India
  • 6 Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer 305801, India. Electronic address: umeshgupta@curaj.ac.in
Drug Discov Today, 2017 Jul 08.
PMID: 28697371 DOI: 10.1016/j.drudis.2017.06.009

Abstract

Highly controllable dendritic structural design means dendrimers are a leading carrier in drug delivery applications. Dendrimer- and other nanocarrier-based hybrid systems are an emerging platform in the field of drug delivery. This review is a compilation of increasing reports of dendrimer interactions, such as dendrimer-liposome, dendrimer-carbon-nanotube, among others, known as hybrid carriers. This should prompt entirely new research with promising results for these hybrid carriers. It is assumed that such emerging hybrid nanosystems - from combining two already-established drug delivery platforms - could lead the way for the development of newer delivery systems with multiple applicability for latent theranostic applications in the future.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications